

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

249-426

APPLICANT

IIDA ET AL.

FILING DATE

April 10, 2006

SERIAL NO.

10/575,261

GROUP

1653 1644

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLAS	YES	NO	TRANSLATION
EP 1 092 037	04/2001	Europe					
WO 03/035835	05/2003	WIPO					
WO 00/62790	10/2000	WIPO					
EP 1 331 266 A1	07/2003	Europe					
WO 00/73481	12/2000	WIPO					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Supplementary Partial European Search Report dated August 2, 2007, issued in connection with EP 04 77 3776.2
	Gawlitze et al, "Ammonium Alters N-Glycan Structures of Recombinant TNFR-IgG: Degradative Versus Biosynthetic Mechanisms", Biotechnology and Bioengineering, June 20, 2000, Vol. 68, No. 6, pp 637-646
	Shinkawa et al, "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity", The Journal of Biological Chemistry, January 31, 2003. Vol. 278, No. 5, pp 3466-3473
	Shields et al, "Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity", The Journal of Biological Chemistry, July 26, 2002, Vol. 277, No. 30, pp 26733-26740
	Murray et al, "Recombinant Human Tumor Necrosis Factor Receptor (p75) Fc Fusion Protein (TNFR:Fc) in Rheumatoid Arthritis", The Annals of Pharmacotherapy, November 1997, Vol. 31, pp 1335-1338
	Shoji-Hosaka et al, "Enhanced Fc-Dependent Cellular Cytotoxicity of Fc Fusion Proteins Derived from TNF Receptor II and LFA-3 by Fucose Removal from Asn-Linked Oligosaccharides", Journal of Biochemistry, December 2006, Vol. 140, No. 6, pp 777-783

Examiner /Chun Dahle/ (08/07/2009) Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)